Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.

Grover, S A

Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. [electronic resource] - Archives of internal medicine Mar 1999 - 593-600 p. digital

Publication Type: Journal Article

0003-9926

10.1001/archinte.159.6.593 doi


Adult
Aged
Canada
Cardiovascular Diseases--economics
Cerebrovascular Disorders--economics
Cost-Benefit Analysis
Drug Costs
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors--economics
Hypolipidemic Agents--economics
Life Expectancy
Male
Middle Aged
Recurrence
Risk
Scandinavian and Nordic Countries
Sensitivity and Specificity
Simvastatin--economics